May 11th 2025
A recently published population-based study reported that patients with MS or NMOSD had a significantly higher risk of autoimmune rheumatic diseases than matched controls.
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in San Diego.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
Muscle MRI May Serve as Sensitive Biomarker for ALS Disease Progression
A study involving 20 patients with ALS found that longitudinal muscle MRI detected progressive atrophy and correlated with muscle strength loss, supporting its potential as a biomarker for ALS progression and clinical trials.
Psychological Perspective on the Role of Mental Health in MS Rehabilitation and Care
May 8th 2025Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.
Case Report Highlights Rare Case of Progressive Multifocal Leukoencephalopathy in Childhood NMOSD
A 17-year-old with NMOSD and rituximab treatment developed PML after several relapses and secondary hypogammaglobulinemia, leading to his death 3 months after diagnosis.
Eric Baron, DO, on the Approval of CT-132: A Digital Shift in Migraine Care
May 6th 2025Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.
Hormonal and Neurological Complexity in Traumatic Brain Injury Recovery for Women
May 4th 2025Christine Greiss, DO, medical director for the Center for Brain injuries at Hackensack Meridian Health, discussed the nuanced impact of hormonal fluctuations, psychological factors, and postmenopausal status on TBI recovery in women.